DNA Methylation Biomarkers as Prediction Tools for Therapeutic Response and Prognosis in Intermediate-Stage Hepatocellular Carcinoma

YI-CHANG LUCHIH-YANG HSIAOPeng, Pey-JeyPey-JeyPengHuang, Shao-ChangShao-ChangHuangChuang, Meng-RongMeng-RongChuangSu, Hung-JuHung-JuSuKAI-WEN HUANG2023-11-272023-11-272023-09-072072-6694https://scholars.lib.ntu.edu.tw/handle/123456789/637397Alfa-fetoprotein (AFP), as the main serum tumor marker of hepatocellular carcinoma (HCC), is limited in terms of specificity and ability to predict outcomes. This study investigated the clinical utility of DNA methylation biomarkers to predict therapeutic responses and prognosis in intermediate-stage HCC.enDNA methylation; hepatocellular carcinoma; locoregional therapy; tumor biomarkerDNA Methylation Biomarkers as Prediction Tools for Therapeutic Response and Prognosis in Intermediate-Stage Hepatocellular Carcinomajournal article10.3390/cancers15184465377604342-s2.0-85172785194https://api.elsevier.com/content/abstract/scopus_id/85172785194